Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Would Share Generic Provigil Exclusivity Under FDA’s Revised Guidelines

Executive Summary

Barr would share exclusivity for its generic version of Cephalon's narcolepsy agent Provigil (modafinil) with three other generic companies under FDA's new guidance redefining "first-to-file" status

You may also be interested in...



Barr Cipro Generic Takes 50% Share; Erosion Slow Under Bayer Deal

Barr's generic ciprofloxacin has captured roughly half of Cipro prescriptions after five weeks on the market

Generic Firms Break Camp; FDA Says “First-To-File” Covers Same-Day ANDAs

FDA's guidance defining "first-to-file" status for generic drug companies launching patent challenges offers some relief for ANDA applicants jockeying for position at the agency - and may offer a further impetus for changes to the current 180-day exclusivity system

Cephalon Provigil for wakefulness

Cephalon's Provigil (modafinil) sNDA to improve wakefulness in patients with excessive sleepiness associated with disorders of sleep and wakefulness will be reviewed by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Sept. 25. Cephalon filed the sNDA for the new indication Dec. 20, 2002; Provigil is currently approved for sleepiness associated with narcolepsy. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8 a.m. [To 1watch a webcast of this meeting, visit FDAAdvisoryCommittee.com]...

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel